Literature DB >> 9096586

Sinusoidal endothelium release of hydrogen peroxide enhances very late antigen-4-mediated melanoma cell adherence and tumor cytotoxicity during interleukin-1 promotion of hepatic melanoma metastasis in mice.

M J Anasagasti1, A Alvarez, J J Martin, L Mendoza, F Vidal-Vanaclocha.   

Abstract

The hepatic sinusoidal endothelium (HSE) releases large amounts of reactive oxygen species (ROS) in response to endotoxins and interleukin-1 (IL-1). Such pro-inflammatory mediators have been shown to promote hepatic metastasis. We have investigated the involvement of ROS released by IL-1-stimulated HSE in this promoting effect. Recombinant human interleukin-1 beta (rHuIL-1 beta) (5 micrograms/kg) was intravenously injected into C57BL/6J mice, and the hepatic metastasizing ability of B16 melanoma cells following intrasplenic injection was studied in the presence of ROS scavengers. rHuIL-1 beta-promoted hepatic metastases were significantly (P < .01) reduced by catalase (1 mg/kg) and enhanced by recombinant human superoxide dismutase (rHuSOD) (5 mg/kg). rHuIL-1 beta-stimulated HSE-conditioned medium (HSE-CM) significantly (P < .01) enhanced B16 melanoma cell adhesion to HSE compared with unstimulated HSE-CM, which in turn also significantly (P < .01) increased with melanoma cell adherence compared with basal medium. The addition of catalase completely abrogated proadhesive effects induced by rHuIL-1 beta-stimulated HSE-CM with respect to unstimulated HSE-CM, but did not affect the proadhesive effects induced by unstimulated HSE-CM over basal medium. The rat monoclonal antibody to mouse vascular cell adhesion molecule-1 (VCAM-1) significantly (P < .01) inhibited the enhanced melanoma cell adherence effects of both unstimulated and rHuIL-1 beta-stimulated HSE-CM, indicating that adherence was very late antigen-4 (VLA-4)-mediated. Not surprisingly, the percentage of VLA-4 expressing B16 melanoma cells significantly (P < .05) increased in response to unstimulated (21% of controls) and rHuIL-1 beta-stimulated (32% of controls) HSE-CM. Catalase addition abrogated these effects of rHuIL-1 beta-stimulated-HSE-CM. Melanoma cell damage was observed from the second hour of adhesion to HSE and significantly (P < .01) increased when the cells adhered to rHuIL-1 beta-stimulated HSE. This increase was abrogated by catalase. Cytolysis of the HSE was not observed during melanoma cell adhesion. Neither was the enhancement of B16 melanoma hydrogen peroxide production observed in response to rHuIL-1 beta. Thus, the effects of IL-1 in the liver may consist of a balance between the prometastatic effect of enhanced adherence to the HSE and the antimetastatic effect of H2O2-mediated cytotoxicity. Our results suggest that the enhancement of H2O2 production by the rHuIL-1 beta-stimulated HSE may contribute to the hepatic metastasis progression of ROS-resistant melanoma cells. Results in vitro indicate that this progression is associated with a H2O2-mediated increase in melanoma cell adhesion to HSE.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096586     DOI: 10.1002/hep.510250410

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  14 in total

Review 1.  Adhesion of lymphocytes to hepatic endothelium.

Authors:  P F Lalor; D H Adams
Journal:  Mol Pathol       Date:  1999-08

2.  IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1.

Authors:  F Vidal-Vanaclocha; G Fantuzzi; L Mendoza; A M Fuentes; M J Anasagasti; J Martín; T Carrascal; P Walsh; L L Reznikov; S H Kim; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

3.  Targets of the tumor suppressor miR-200 in regulation of the epithelial-mesenchymal transition in cancer.

Authors:  Mark J Schliekelman; Don L Gibbons; Vitor M Faca; Chad J Creighton; Zain H Rizvi; Qing Zhang; Chee-Hong Wong; Hong Wang; Christin Ungewiss; Young-Ho Ahn; Dong-Hoon Shin; Jonathan M Kurie; Samir M Hanash
Journal:  Cancer Res       Date:  2011-10-10       Impact factor: 12.701

4.  The liver prometastatic reaction of cancer patients: implications for microenvironment-dependent colon cancer gene regulation.

Authors:  Fernando Vidal-Vanaclocha
Journal:  Cancer Microenviron       Date:  2011-08-26

5.  Does Pringle maneuver affect survival in patients with colorectal liver metastases?

Authors:  Alessandro Ferrero; Nadia Russolillo; Luca Viganò; Roberto Lo Tesoriere; Andrea Muratore; Lorenzo Capussotti
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

6.  IL-1 is required for tumor invasiveness and angiogenesis.

Authors:  Elena Voronov; Dror S Shouval; Yakov Krelin; Emanuela Cagnano; Daniel Benharroch; Yoichiro Iwakura; Charles A Dinarello; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-21       Impact factor: 11.205

7.  Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice.

Authors:  Makiya Nishikawa; Ayumi Tamada; Kenji Hyoudou; Yukari Umeyama; Yuki Takahashi; Yuki Kobayashi; Hitomi Kumai; Emi Ishida; Frantisek Staud; Yoshiyuki Yabe; Yoshinobu Takakura; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

8.  Arrest of B16 melanoma cells in the mouse pulmonary microcirculation induces endothelial nitric oxide synthase-dependent nitric oxide release that is cytotoxic to the tumor cells.

Authors:  Hongming Qiu; F William Orr; Derrek Jensen; Hui Helen Wang; Alan R McIntosh; Brian B Hasinoff; Dwight M Nance; Susan Pylypas; Ke Qi; Chun Song; Ruth J Muschel; Abu-Bakr Al-Mehdi
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

9.  IL-18 regulates melanoma VLA-4 integrin activation through a Hierarchized sequence of inflammatory factors.

Authors:  María Valcárcel; Teresa Carrascal; Olatz Crende; Fernando Vidal-Vanaclocha
Journal:  J Invest Dermatol       Date:  2013-08-12       Impact factor: 8.551

10.  The prometastatic microenvironment of the liver.

Authors:  Fernando Vidal-Vanaclocha
Journal:  Cancer Microenviron       Date:  2008-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.